If the endocytotic and endosomal escape capabilities are validated in the coming months Phylogica will finally have created something very valuable to big pharma and in-particular Janssen (Johnson & Johnson).
Agree. I'd also add that Phylogica are progressing their studies on the BEN_5000 Phylomer with Roche/Genentech. If they are are currently applying the endosomal escape technology in the Roche/Genentech project, you're right, what's to say this isn't being applied in the Janssen program with the second generation customised libraries or to their in-house projects.
Regards, Tony
PYC Price at posting:
1.4¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)